Messenger RNA-1273 Moderna COVID-19 Vaccination as Potential Trigger for Case of New Onset Pemphigus Vulgaris
Largo Medical Center
pemphigus vulgaris, COVID-19 mRNA vaccine, moderna vaccine, autoimmune disorder, autoimmune bullous disease, mRNA-1273 vaccine
Dermatology | Skin and Connective Tissue Diseases
As vaccination against Coronavirus 2019 (COVID-19) remains a worldwide initiative, so does describing its associated adverse effects. While there have been many reports detailing various dermatologic adverse events, autoimmune bullous disorders following vaccination are less well described.1 Pemphigus vulgaris (PV) is an autoimmune bullous disease of the skin and mucous membranes that has many known triggers, including vaccination.2 To our knowledge, there are at least six cases of pemphigus vulgaris developing following SARS-Cov-2 vaccination.3 Here we describe a case of new onset PV following COVID-19 vaccination with the mRNA-1273 (Moderna) vaccine. Because this disease carries significant morbidity and mortality, we hope this report serves as a reminder that while vaccination remains a global priority, continued documentation and recognition of novel vaccination side effects by clinicians is essential.
Publisher or Conference
Skin: The Journal of Cutaneous Medicine
Holt S, Meckley A, Harp T, Esguerra D. Messenger RNA-1273 Moderna COVID-19 Vaccination as Potential Trigger for Case of New Onset Pemphigus Vulgaris. SKIN. 2022;6(5):415-417. doi: 10.25251/skin.6.5.11